NBTX Stock — Nanobiotix

Nanobiotix (NBTX)

Updated October 16, 2026.

NBTX is a Stock. Total return is 25.4% over the past 5.8 years, 100.5 points behind SPY at 125.9%.

Nanobiotix is a clinical-stage biotechnology company based in Paris that develops product candidates for cancer treatment, with its lead program being NBTXR3, a nanoparticle therapy in development for multiple solid tumors including soft tissue sarcoma, head and neck cancer, and lung cancer; the company has partnered with Lian Oncology to advance this candidate in China and select Asian markets. The company does not currently distribute to shareholders. This security appeals to investors with high risk tolerance seeking exposure to early-stage cancer research and development.

NBTX performance versus SPY

Price and return data through 2026-10-16.

Total return is 25.4% over the past 5.8 years, 100.5 points behind SPY at 125.9%. Over the past year its total return — price change plus distributions reinvested — is -19.8%. Its deepest 1-year drawdown was 61.4%.

NBTX key facts

Asset type

Stock

Asset class

Equity

Inception date

12/11/2020

Distribution frequency

None

Last close

$21.30 (as of 2026-10-16)

Market cap

$1,084,583,433

Average volume

77771.0

Beta

0.591

Payout ratio

0.0%

Forward P/E

42.3729

EPS

$-1.27

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NBTX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 61.4%.

Who may consider NBTX — and who may not

It is a weaker fit for investors who need monthly cash flow (NBTX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NBTX

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions